Genfit Joins Euronext Paris CAC Mid 60 and SBF 120 Indices
The Scientific Index Council of Euronext Paris has decided to admit the Lille-based biopharmaceutical company to two of its indices following the annual review. The change will take effect after the close of trading on September 18, 2026.
Admission to CAC Mid 60 and SBF 120 Following Annual Review
Genfit announced on September 11, 2026 its admission to the CAC Mid 60 and SBF 120 indices of Euronext Paris, a decision made by the Scientific Index Council as part of the annual review.
These changes will become effective after market close on September 18, 2026. The CAC Mid 60 and SBF 120 are among the most widely followed indices of Euronext Paris, representing mid-cap stocks and an expanded selection of 120 large-cap values respectively.
An Inclusion Linked to Capitalization, Liquidity and Visibility
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
According to the company, admission to the SBF 120 reflects the increase in its market capitalization, liquidity and visibility. It is intended to strengthen the company's profile among institutional investors.
Pascal Prigent, Chief Executive Officer of Genfit, stated that this inclusion comes following positive momentum and growing investor confidence in the company's strategy and its ability to execute it. He linked this milestone to the company's commitment to therapies and diagnostic solutions for patients suffering from rare and potentially life-threatening liver diseases.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T1 2026
Key reported figures
Revenue: 9,6 millions d'euros
Quarterly revenue: 9,6 millions d'euros
Revenue growth: 242,9 %
Risks mentioned
Dépendance aux partenaires pour le développement commercial.
Opportunities identified
Dynamique favorable des ventes d'Iqirvo renforçant les marges financières.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
